[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606350":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":26,"locations":34,"responsibleParty":46,"collaborators":49,"id":59,"slug":26,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":26,"enrollmentInfo":67,"targetDuration":26,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":26,"overallStatus":82,"whyStopped":26,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Stanford University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cilostazol 100mg","EXPERIMENTAL","Participants take oral cilostazol until a study endpoint occurs, they reach maximum follow up duration (4 years), the participant withdraws, or the study ends.",[13],"Drug: Cilostazol 100 mg",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants take oral placebo until a study endpoint occurs, they reach maximum follow up duration (4 years), the participant withdraws, or the study ends.",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Cilostazol 100 mg","Cilostazol 100 mg tablet taken orally twice daily following an initial 2-week period during which cilostazol is dosed at 100 mg tablet taken orally once daily to maximize tolerability.",[9],null,{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":26},"Placebo 100 mg tablet twice taken orally daily following an initial 2-week period during which placebo is dosed at 100 mg taken orally once daily to maximize tolerability.",[15],[31],{"name":32,"affiliation":5,"role":33},"Maarten Lansberg, MD, PhD","PRINCIPAL_INVESTIGATOR",[35],{"facility":5,"status":26,"city":36,"state":37,"zip":38,"country":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":26},"Stanford","California","94305","United States",{"type":41,"coordinates":42},"Point",[43,44],-122.16608,37.42411,{"lat":44,"lon":43},{"type":33,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Maarten Lansberg","Professor of Neurology",[50,53,55,57],{"name":51,"class":52},"National Institute of Neurological Disorders and Stroke (NINDS)","NIH",{"name":54,"class":6},"Yale University",{"name":56,"class":6},"University of Cincinnati",{"name":58,"class":6},"Medical University of South Carolina","100606350",false,"NCT07174414","Cilostazol for Prevention of Recurrent Stroke Trial","Clarity","Inclusion Criteria:\n\n* Diagnosis of stroke or mini-stroke (also called TIA) within the last 180 days\n* Currently taking aspirin or clopidogrel (not both) to prevent another stroke\n\nExclusion Criteria:\n\n* Had a spontaneous brain bleed within the last 2 years.\n* Moderate to severe heart failure.\n* Life expectancy is less than 6 months.","ALL","40 Years",{"count":68,"type":69},2000,"ESTIMATED","INTERVENTIONAL",[72],"PHASE3","The goal of this clinical trial is to learn whether adding cilostazol to aspirin or clopidogrel prevents stroke and heart attack in people who have had a stroke or mini-stroke.",[75,76,77,78,79,80,81],"Stroke Recurrence","Myocardial Infarction","Vascular Death","Ischemic Stroke","TIA (Transient Ischemic Attack)","Stroke (CVA) or Transient Ischemic Attack","Recurrent Stroke","NOT_YET_RECRUITING","2025-09-12",{"date":85,"type":86},"2025-09-16","ACTUAL",{"date":88,"type":69},"2026-08",{"date":90,"type":69},"2031-07",{"name":5,"class":6},1]